M channels containing KCNQ2 subunits modulate norepinephrine, aspartate, and GABA release from hippocampal nerve terminals

J Neurosci. 2004 Jan 21;24(3):592-7. doi: 10.1523/JNEUROSCI.3143-03.2004.

Abstract

KCNQ subunits encode for the M current (I(KM)), a neuron-specific voltage-dependent K+ current with a well established role in the control of neuronal excitability. In this study, by means of a combined biochemical, pharmacological, and electrophysiological approach, the role of presynaptic I(KM) in the release of previously taken up tritiated norepineprine (NE), GABA, and d-aspartate (d-ASP) from hippocampal nerve terminals (synaptosomes) has been evaluated. Retigabine (RT) (0.01-30 microm), a specific activator of I(KM), inhibited [3H]NE, [3H]d-ASP, and [3H]GABA release evoked by 9 mm extracellular K+ ([K+]e). RT-induced inhibition of [3H]NE release was prevented by synaptosomal entrapment of polyclonal antibodies directed against KCNQ2 subunits, an effect that was abolished by antibody preabsorption with the KCNQ2 immunizing peptide; antibodies against KCNQ3 subunits were ineffective. Flupirtine (FP), a structural analog of RT, also inhibited 9 mm [K+]e-induced [3H]NE release, although its maximal inhibition was lower than that of RT. Electrophysiological studies in KCNQ2-transfected Chinese hamster ovary cells revealed that RT and FP (10 microm) caused a -19 and -9 mV hyperpolarizing shift, respectively, in the voltage dependence of activation of KCNQ2 K+ channels. In the same cells, the cognition enhancer 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone (XE-991) (10 microm) blocked KCNQ2 channels and prevented their activation by RT (1-10 microm). Finally, both XE-991 (10-100 microm) and tetraethylammonium ions (100 microm) abolished the inhibitory effect of RT (1 microm) on [3H]NE release. These findings provide novel evidence for a major regulatory role of KCNQ2 K+ channel subunits in neurotransmitter release from rat hippocampal nerve endings.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminopyridines / pharmacology
  • Animals
  • Anthracenes / pharmacology
  • Anticonvulsants / pharmacology
  • Aspartic Acid / chemistry
  • Aspartic Acid / metabolism*
  • CHO Cells
  • Carbamates / pharmacology
  • Cricetinae
  • Hippocampus / chemistry
  • Hippocampus / metabolism
  • KCNQ2 Potassium Channel
  • KCNQ3 Potassium Channel
  • Male
  • Norepinephrine / chemistry
  • Norepinephrine / metabolism*
  • Patch-Clamp Techniques
  • Phenylenediamines / pharmacology
  • Potassium / metabolism
  • Potassium Channel Blockers / pharmacology
  • Potassium Channels / chemistry
  • Potassium Channels / drug effects
  • Potassium Channels / metabolism*
  • Potassium Channels, Voltage-Gated
  • Presynaptic Terminals / chemistry
  • Presynaptic Terminals / metabolism*
  • Protein Subunits / chemistry
  • Protein Subunits / metabolism
  • Rats
  • Synaptosomes / chemistry
  • Synaptosomes / drug effects
  • Synaptosomes / metabolism
  • gamma-Aminobutyric Acid / chemistry
  • gamma-Aminobutyric Acid / metabolism*

Substances

  • 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone
  • Aminopyridines
  • Anthracenes
  • Anticonvulsants
  • Carbamates
  • KCNQ2 Potassium Channel
  • KCNQ3 Potassium Channel
  • Kcnq2 protein, rat
  • Kcnq3 protein, rat
  • Phenylenediamines
  • Potassium Channel Blockers
  • Potassium Channels
  • Potassium Channels, Voltage-Gated
  • Protein Subunits
  • ezogabine
  • Aspartic Acid
  • gamma-Aminobutyric Acid
  • flupirtine
  • Potassium
  • Norepinephrine